Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on April 6, 2017. The filing addresses a change in senior management, specifically the appointment of an interim Chief Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Departure: W. Bradford Smith resigned as Chief Financial Officer effective March 31, 2017.
- Interim Appointment: James Fortune, Chief Operating Officer, served as interim principal financial officer and principal accounting officer from April 1, 2017, to April 6, 2017.
- New Appointment: George Migausky was appointed as interim Chief Financial Officer effective April 6, 2017.
Management Commentary and Compensation
Mr. Migausky will serve on a part-time basis (approximately 50%) with an annualized base salary of $299,000. He has extensive prior experience as a CFO in the biotechnology and life sciences sectors, including roles at Dyax Corp., Wellstat Management Company, IGEN International, and BioVeris Corporation. The Company has entered into a standard Indemnification Agreement with Mr. Migausky, which may require the Company to indemnify him for expenses, judgments, fines, and settlement amounts arising from his service as an officer.
Investor Verification Checklist
- Verify the effective dates of the CFO transition (Smith's resignation vs. Migausky's appointment).
- Confirm the part-time nature (50%) and specific compensation terms ($299,000 annualized) of the new interim CFO.
- Review the Indemnification Agreement (Exhibit 10.12) for potential financial liabilities to the Company.
- Assess the impact of the CFO vacancy period (March 31 to April 6) on financial reporting timelines.